BillionToOne, Inc.
BLLNNasdaq
$130.31
↑ +1.7%Jul 17 close · end-of-day
Price
1Y↑ +19.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.8B
Enterprise Value
$2.3B
P/E
930.8
P/S
9.1
P/B
5.5
EV/EBITDA
101.2
PEG
—
FCF Yield
0.6%
Dividend Yield
—
Revenue (TTM)
$305.1M
Net Income (TTM)
$7.5M
Free Cash Flow (TTM)
$15.7M
Gross Margin
68.3%
Operating Margin
5.3%
Net Margin
2.4%
ROE
1.5%
ROIC
26.5%
Debt / Equity
0.2
Net Cash
$447.4M
Return 1Y
—
Company profile
BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule NGS (smNGS) platform achieves what was once thought impossible – detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented QCTs, enabling measurements at the physical limit of detection – the single DNA molecule. Our principal executive offices are located in Menlo Park, CA.
- CEO
- Oguzhan Atay
- Sector
- Services
- Industry
- Healthcare
- Employees
- 620
- Headquarters
- California
- Website
- www.billiontoone.com
Management & directors
- Tsao DavidChief Technology Officer
- Ten Bosch John RoderickSVP of Laboratory Operations
- Atay OguzhanChairman and CEO
- Sakakibara Shan RikuChief Product Officer
- Johnson Nancy JoannSee Remarks
- Lynch Thomas P.See Remarks
Roles derived from SEC Form 4 filings.
Earnings
BLLN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$108.4M↑ +83.8%
Diluted EPS$0.34↓ -187.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $71.7M | $152.6M | $305.1M |
| Gross profit | $17.3M | $80.9M | $208.5M |
| Operating income | -$69.5M | -$47.1M | $16.0M |
| Net income | -$82.7M | -$41.6M | $7.5M |
| Diluted EPS | -$8.45 | -$4.12 | $0.14 |
| Operating cash flow | -$53.7M | -$41.4M | $24.6M |
| Free cash flow | -$59.8M | -$46.8M | $15.7M |
| Gross margin | 24.1% | 53.0% | 68.3% |
| Operating margin | -96.9% | -30.9% | 5.3% |
| Net margin | -115.3% | -27.2% | 2.4% |
| Line item | Q3 '24 | Q1 '25 | Q3 '25 | Q1 '26 |
|---|---|---|---|---|
| Revenue | $38.4M | $59.0M | $83.5M | $108.4M |
| Gross profit | $20.2M | $38.0M | $58.4M | $79.1M |
| Operating income | -$12.6M | -$2.3M | $9.6M | $17.8M |
| Net income | -$14.9M | -$4.0M | $5.7M | $18.0M |
| Diluted EPS | -$1.47 | -$0.39 | $0.10 | $0.34 |
| Operating cash flow | — | $2.6M | — | $15.4M |
| Free cash flow | — | $278,000.00 | — | $11.0M |
| Gross margin | 52.6% | 64.4% | 69.9% | 73.0% |
| Operating margin | -32.9% | -3.9% | 11.5% | 16.5% |
| Net margin | -38.8% | -6.8% | 6.8% | 16.6% |
Company news
Jul 15, 2026
Jul 6, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-13 | Tsao David· Chief Technology Officer | Sale | 3,835 | $125.76 | $482,285.00 | filing |
| 2026-07-13 | Tsao David· Chief Technology Officer | Sale | 3,185 | $125.85 | $400,818.87 | filing |
| 2026-07-13 | Tsao David· Chief Technology Officer | Sale | 2,477 | $123.84 | $306,760.35 | filing |
| 2026-07-13 | Tsao David· Chief Technology Officer | Sale | 2,415 | $124.90 | $301,632.53 | filing |
| 2026-07-13 | Tsao David· Chief Technology Officer | Sale | 2,274 | $123.71 | $281,313.81 | filing |
| 2026-07-13 | Tsao David· Chief Technology Officer | Sale | 1,725 | $124.65 | $215,027.81 | filing |
| 2026-07-13 | ten Bosch John Roderick· SVP of Laboratory Operations | Sale | 1,417 | $125.46 | $177,776.82 | filing |
| 2026-07-13 | ten Bosch John Roderick· SVP of Laboratory Operations | Sale | 1,417 | $125.46 | $177,776.82 | filing |
| 2026-07-13 | ten Bosch John Roderick· SVP of Laboratory Operations | Sale | 1,417 | $125.46 | $177,776.82 | filing |
| 2026-07-13 | Tsao David· Chief Technology Officer | Sale | 1,138 | $122.84 | $139,795.11 | filing |
| 2026-07-13 | Tsao David· Chief Technology Officer | Sale | 1,102 | $122.90 | $135,440.76 | filing |
| 2026-07-13 | Tsao David· Chief Technology Officer | Sale | 1,028 | $126.90 | $130,448.27 | filing |
| 2026-07-13 | Tsao David· Chief Technology Officer | Sale | 821 | $126.89 | $104,175.05 | filing |
| 2026-07-13 | Tsao David· Chief Technology Officer | Option exercise | 10,000 | $2.80 | $28,000.00 | filing |
| 2026-07-13 | Tsao David· Chief Technology Officer | Option exercise | 10,000 | $2.80 | $28,000.00 | filing |
| 2026-07-09 | Atay Oguzhan· Chairman and CEO | Sale | 7,489 | $125.43 | $939,318.31 | filing |
| 2026-07-09 | Sakakibara Shan Riku· Chief Product Officer | Sale | 4,000 | $125.00 | $500,000.00 | filing |
| 2026-07-09 | Atay Oguzhan· Chairman and CEO | Sale | 2,657 | $127.44 | $338,599.05 | filing |
| 2026-07-09 | Atay Oguzhan· Chairman and CEO | Sale | 2,002 | $126.48 | $253,220.77 | filing |
| 2026-07-09 | Sakakibara Shan Riku· Chief Product Officer | Sale | 1,355 | $125.00 | $169,375.00 | filing |
| 2026-07-09 | Sakakibara Shan Riku· Chief Product Officer | Sale | 1,354 | $125.00 | $169,250.00 | filing |
| 2026-07-09 | Sakakibara Shan Riku· Chief Product Officer | Sale | 1,117 | $125.00 | $139,625.00 | filing |
| 2026-07-09 | Atay Oguzhan· Chairman and CEO | Sale | 352 | $128.23 | $45,137.59 | filing |
| 2026-07-09 | Sakakibara Shan Riku· Chief Product Officer | Option exercise | 1,355 | $30.78 | $41,706.90 | filing |
| 2026-07-09 | Sakakibara Shan Riku· Chief Product Officer | Option exercise | 1,354 | $30.78 | $41,676.12 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.